首页 | 本学科首页   官方微博 | 高级检索  
     


Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind,randomised controlled trial
Authors:Martin Reck  Rolf Kaiser  Anders Mellemgaard  Jean-Yves Douillard  Sergey Orlov  Maciej Krzakowski  Joachim von Pawel  Maya Gottfried  Igor Bondarenko  Meilin Liao  Claudia-Nanette Gann  José Barrueco  Birgit Gaschler-Markefski  Silvia Novello
Affiliation:1. Department of Thoracic Oncology, Lung Clinic Grosshansdorf, Grosshansdorf, Germany;2. German Centre for Lung Research, Grosshansdorf, Germany;3. Corporate Division Medicine, TA Oncology, Boehringer Ingelheim Pharma, Biberach an der Riss, Germany;4. Medical Data Services and Biostatistics, Boehringer Ingelheim Pharma, Biberach an der Riss, Germany;5. Department of Oncology, Herlev University Hospital, Herlev, Denmark;6. Department of Medical Oncology, Centre ICO René Gauducheau, Nantes, France;7. Department of Thoracic Oncology, St Petersburg State Medical University, St Petersburg, Russia;8. The Maria Sklodowska-Curie Institute of Oncology, Warsaw, Poland;9. Pneumology Clinic, Asklepios Fachkliniken Munchen-Gauting, Gauting, Germany;10. Lung Cancer Unit, Meir Medical Centre, Kfar Saba, Israel;11. Clinical Facility, Dnepropetrovsk Medical Academy, Dnepropetrovsk Municipal Clinical Hospital no 4, Dnepropetrovsk, Ukraine;12. Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China;13. Department of Medical Affairs, Boehringer Ingelheim Pharma, Ingelheim, Germany;14. Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT, USA;15. Department of Oncology, University of Turin, AUO San Luigi, Orbassano, Italy
Abstract:
Keywords:
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号